Race Oncology Non-Executive Director Dr. John Cullity speaks with Proactive Investors about the company’s cancer chemotherapy drug, Bisantrene. Watch the video here.
New Race non-executive director Dr John Cullity has used his first interview to highlight the company’s growth potential. View the interview on YouTube.
Race Oncology’s second Bisantrene patent has received “Notice of Allowance” in the US. Once ‘allowed’ in a jurisdiction, a patent can proceed to a ‘granted’ patent. The patent titled,